Novo Nordisk’s Wegovy (semaglutide), a GLP-1 weight loss drug. Photographer: George Frey/Bloomberg
© 2023 Bloomberg Finance LP
California recently passed a budget for 2025-2026 that eliminates Medicaid coverage for GLP-1 agonists for weight loss. Other states are considering similar cuts. States are struggling to close gaps in budgets. Enactment of The Big Beautiful Bill will likely add pressure on budget finances. It’s hard to envision a scenario in which state Medicaid agencies expand…
Continue Reading
News Source: www.forbes.com

Leave a Reply